Evidence & regulatory context
- Mechanism
- Broad-spectrum matrix metalloproteinase (MMP) inhibitor; no ChEMBL mechanism record.
- Target
- Not recorded
- Injury models
- Radiation · Ischaemia-reperfusion
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Preclinical/no trial
- ChEMBL record
- CHEMBL19611 ↗
- ChEMBL max phase
- 2 / 4 (development scale, not regulatory approval)
- Synonyms
- Galardin; GM6001
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 2
2 studies reported at therapy level; 2 evidence entries itemised.
MouseRadiationPretreatment before total body irradiation
Model: Total body gamma irradiation, including 6 Gy whole body irradiation
Ilomastat treatment increased survival of mice after total body irradiation, and pretreatment promoted recovery of haematological and immunological cells after 6 Gy gamma irradiation.
Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.
MouseIschaemia-reperfusionCerebral (MCAO/stroke)
Model: Prolonged cerebral hypoperfusion stress leading to white matter demyelination
GM6001 reduced early blood-brain barrier leakage and neutrophil infiltration after cerebral hypoperfusion, indicating that oligodendrocyte precursor derived MMP9 drives early barrier disruption.
Extraction: extract · Subtype source: llm · Supplied extraction confidence: 0.5. Machine-extracted fields require source verification.
